PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) narrowed its third-quarter net loss by 32% to $23.5 million as it reduced research spending and prepared two experimental cell therapies for clinical development, with sufficient cash to fund operations into early 2029.
The Philadelphia biotechnology company reported a net loss of $34.4 million in the comparable 2025 quarter. Research and development expenses declined to $18.1 million from $22.5 million, reflecting reductions in personnel and facility costs following a restructuring of its development priorities.
General and administrative expenses increased to $7.1 million from $6.8 million.
Century ended September with $174.1 million in cash, cash equivalents and investments, up from $117.1 million at the end of 2025. The company expects those resources to support operations into the first quarter of 2029.
The financial results come as Century prepares to advance CNTY-813, an investigational islet cell replacement therapy for type 1 diabetes, into human testing.
The company expects to submit an investigational new drug application to the Food and Drug Administration during the fourth quarter of 2026, with initial clinical safety and efficacy data anticipated in the second half of 2027.
Century said it reached general alignment with the FDA on the therapy’s nonclinical testing package, manufacturing process and proposed Phase 1/2 clinical trial design following a pre-IND meeting.
CNTY-813 uses induced pluripotent stem cells engineered to produce insulin-secreting islet cells. The treatment is intended to restore insulin production in patients with type 1 diabetes.
Nonclinical results presented at the 62nd annual meeting of the European Association for the Study of Diabetes showed that CNTY-813 restored normal blood glucose levels in diabetic mice and maintained control until the transplanted cells were removed in a study lasting more than 11 months.
All treated diabetic mice achieved normal blood glucose levels, while laboratory testing showed insulin secretion responses comparable to primary islet cells.
Century also reported consistent product characteristics across five clinical-scale manufacturing batches, with the final product exceeding purity requirements.
Additional studies demonstrated that transplanted cells engrafted in rat livers and expressed markers associated with insulin-producing and endocrine cells.
In another mouse study, cells stored under refrigerated conditions for 96 hours restored normal blood glucose within 30 days, with the effect maintained through three months of follow-up. The findings support the company’s proposed clinical distribution process.
Century is separately preparing CNTY-308, an investigational CD19-targeted CAR-iT cell therapy for autoimmune diseases, to enter clinical testing before the end of 2026.
The company said it has aligned with health authorities on nonclinical requirements, manufacturing and Phase 1 trial parameters.
Preclinical studies found CNTY-308 performed comparably to patient-derived CAR-T cells in measures including cell proliferation, cytokine secretion and persistence.
“With general alignment reached with the FDA for both programs, we remain on track this year for clinical entry of CNTY-308 and IND submission of CNTY-813,” said Brent Pfeiffenberger, Century’s chief executive officer.
Both therapies incorporate the company’s engineered cell technology, designed to support the development of treatments derived from donor-independent stem cell sources.
Century also appointed Joseph Truitt to its board of directors. Truitt is chief executive officer of iECURE and chairman of Larimar Therapeutics, and previously led BioSpecifics Technologies and Achillion Pharmaceuticals.
The company’s upcoming regulatory submissions and clinical trials will determine whether the results observed in laboratory and animal studies can translate into safety and therapeutic benefits in patients.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
